Risk of Colitis in Patients With Inflammatory Bowel Disease or Microscopic Colitis Exposed to Checkpoint Inhibitors:
Emilie Kristine Dahl1,2, Katrine Risager Christensen2,3, Henrik Albæk Jacobsen4
1Department of Digestive Diseases, Transplantation and General Surgery, Rigshospitalet, Denmark.
Purpose:
Patients with intestinal inflammatory diseases such as ulcerative colitis (UC), Crohn's disease (CD), and microscopic colitis (MC) are excluded from clinical trials with immune checkpoint inhibitors (ICI) because of concerns of exacerbating their underlying immune-mediated disease. This study evaluated the risk of developing disease activity or checkpoint inhibitor checkpoint inhibitor-mediated enterocolitis (IMC).
Materials And Methods:
We performed a nationwide, retrospective cohort study in Denmark, analyzing patients with UC, CD, and MC diagnosed with cancer and treated with ICIs between 2010 and 2024.
Results:
Eighty-five patients were included, and IMC was observed in 39 (46%) patients. Of these, 15 cases were mild, allowing 61 (72%) patients to continue ICI treatment. Multivariate logistic analysis showed that patients with CD had a lower odds ratio (OR) for developing IMC compared with patients with UC and MC (OR, 0.07, P = .02). When compared with a control cohort without intestinal disease (n = 81), patients with UC, CD, and MC had a significantly higher risk of developing IMC when treated with anti-PD-1/anti-PD-L1 inhibitors, with a hazard ratio of 4.93, P < .001.
Conclusion:
Patients with CD appear to have a lower risk of IMC than those with UC and MC. Despite an increased risk of IMC and severe IMC in patients with UC, CD, and MC, 72% of the patients were able to continue first-line treatment with ICI. Treatment with ICI in patients with UC, CD, and MC is overall well tolerated and should be considered on the basis of the same criteria as in patients without intestinal diseases.
More Related Videos
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...